New York, May 21, 2026, 08:08 (EDT)
Vanda Pharmaceuticals slipped in early premarket trading on Thursday, giving back a sliver of Wednesday’s 3.2% gain, as investors weighed the Nasdaq-listed drugmaker’s latest investor meetings against the cost of rolling out new medicines. The stock was shown at $6.15 before the bell, down 0.5%, after closing at $6.18 on Wednesday.
That matters now because Vanda is moving from approval news to sales proof. The Washington-based company has added Nereus for vomiting induced by motion and Bysanti for schizophrenia and acute bipolar I disorder to a commercial portfolio that already includes Fanapt, Hetlioz and Ponvory.
Thursday is not a scheduled U.S. market holiday. Nasdaq’s 2026 calendar lists Memorial Day, Monday, May 25, as the next full market closure, leaving investors with two regular sessions before the long weekend.
The immediate calendar has been busy rather than dramatic. Vanda’s investor site listed a H.C. Wainwright BioConnect fireside chat at Nasdaq on May 19, and the company also said it would attend B. Riley’s investor conference in California on May 20.
Vanda’s latest hard numbers came earlier this month. First-quarter net product sales rose 3% to $51.7 million, Fanapt sales climbed 26% to $29.6 million, Hetlioz fell 24% to $15.9 million, and loss before income taxes widened to $48.4 million. Mihael H. Polymeropoulos, Vanda’s president, CEO and chairman, called the quarter one of “strong commercial execution.” PR Newswire
The company raised its 2026 revenue guidance to $240 million to $290 million from $230 million to $260 million. It now expects Nereus to contribute $10 million to $30 million this year, while leaving its Fanapt forecast at $150 million to $170 million. Guidance is a company’s own estimate, not a guarantee.
Nereus is the more consumer-facing story. Reuters reported in December that the FDA approved the drug as the first treatment for motion-induced vomiting to get U.S. approval in more than 40 years. H.C. Wainwright analyst Raghuram Selvaraju said sales in that indication “could exceed $100 million annually” at U.S. peak. Reuters
Bysanti gives Vanda another shot in psychiatry, but the market is crowded. Reuters has noted Bristol Myers Squibb’s Cobenfy and Johnson & Johnson’s Caplyta among rival approved antipsychotics; Jefferies analyst Andrew Tsai also flagged a harder question, saying Bysanti is “essentially more or less the same drug” as Fanapt, with similar efficacy and safety. Reuters
But the downside case is plain. Launches cost money, and Vanda used $50.2 million in operating cash during the first quarter while posting a $48.6 million net loss. If Nereus uptake is slower than hoped, if Bysanti fails to separate itself from Fanapt, or if Hetlioz keeps weakening, the stock’s approval-led rebound could run into a funding and execution test.
For now, VNDA remains a small-cap biotech trade, not a broad market bellwether. StockAnalysis listed its market value near $372 million and its 52-week range at $4.14 to $9.94, leaving room for sharp moves on launch updates, analyst notes or conference commentary.
